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Abstract
Pneumococcal infections, including pneumonia and invasive disease, are major sources of morbidity and mortality worldwide. Prevention of
the ﬁrst acquisition of Streptococcus pneumoniae through the use of vaccines represents an effective method to reduce the burden of the
disease in both children and adults. Two vaccines are currently available in adults: a pneumococcal polysaccharide vaccine (PPV23) that
includes 23 puriﬁed capsular polysaccharide antigens and a pneumococcal protein-conjugate vaccine (PCV13) that includes capsular
polysaccharide antigens covalently linked to a non-toxic protein. The PPV23 induces a humoral immune response and since it has been
licensed has been the subject of debates and controversies. Numerous studies and meta-analyses have shown that PPV23 protects against
invasive pneumococcal disease, although there are conﬂicting data regarding its efﬁcacy for the prevention of pneumonia. Vaccination with
PCV13 stimulates good antibody responses as well as mucosal immunity and suppresses colonization. A conjugate vaccine can be expected
to have beneﬁts over a polysaccharide vaccine because of the characteristics of a T-cell-dependent response in terms of afﬁnity, maturation
of antibodies with repeated exposure, induction of immunological memory and long-lasting immunity. PCV13 has demonstrated all of these
characteristics in children and fundamental differences in adults are not expected. The efﬁcacy in adults is currently being investigated and
results will be available soon.
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Introduction
Infections due to Streptococcus pneumoniae represent one of
the major causes of morbidity and mortality worldwide [1,2].
Pneumococcal disease can be broadly grouped into categories
of non-invasive pneumococcal disease, also termed mucosal
infection (otitis, sinusitis and pneumonia without bacteraemia),
and invasive pneumococcal disease (IPD) occurring when the
organism invades normally sterile sites, such as bloodstream
infection, pneumonia with bacteraemia and infection of the
meninges. In subjects with chronic medical conditions, the
incidence of IPD rises to 176–483/100 000 persons, and
reaches 342–2031/100 000 persons among immunosup-
pressed patients [3,4]. Pneumococcal infections show a
bimodal distribution, with high prevalence in both children
and the elderly. The incidence of IPD is affected by a number of
factors, including smoking status, immune function, age and
geographical location [5]. Even when appropriate antibiotic
treatment is instituted, mortality due to IPD remains high,
involving 10–25% of patients [6].
Most of the burden of pneumococcal disease in adults is
related to pneumonia, which represents a major respiratory
tract infection with a high prevalence in the general population
and with clinical heterogeneity and variable severity [7,8].
Although the use of antibiotics is necessary for the treatment
of pneumococcal infections, the level of antibiotic resistance in
S. pneumoniae is increasing and the current development
programme for new antibiotics will not provide new drugs in
the near future.
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Is it possible to improve the management of patients with
pneumococcal infections?
It could be argued that both early diagnosis and treatment
together represent the cornerstone in the management of
pneumococcal infections and they could reduce the burden
of pneumococcal disease. However, microbiological diagnosis
of S. pneumoniae infection is usually reached in a low
percentage of patients with community-acquired pneumonia
[9,10].
The identiﬁcation of S. pneumoniae rarely leads to a change
in empiric antibiotic therapy. When a change in antibiotic
therapy is necessary, this intervention does not appear to
affect the patients’ prognosis, probably because of the latency
between the time of the onset of infection and the time of
microbiological diagnosis [11].
Streptococcus pneumoniae is part of the commensal ﬂora of
the upper respiratory tract and colonizes the nasopharyngeal
niche. Colonization seems to be an important feature because
pneumococcal disease will not occur without the preceding
nasopharyngeal colonization [12]. Streptococcus pneumoniae
colonization occurs early in infancy and rapidly spreads among
children and family members. For this reason, prevention of
ﬁrst acquisition of S. pneumoniae among children with the use
of a vaccine represents an effective method to reduce the
infection in both child and adult populations.
The design of a pneumococcal vaccine
The design of a pneumococcal vaccine is an important
challenge, with the main concern being the high number of
different serotypes. Data from the Tigecycline Evaluation
Surveillance Trial (TEST) have shown that among the 92
different serotypes, the most common in children were 19A,
19F and 14, whereas the most common among adults were
19A, 3, 6A and 7F [13]. Some serotypes seem to favour
speciﬁc organs: serotypes 1 and 3 are more often isolated from
the lung during pneumonia, whereas serotypes 6, 10 and 23
are regularly isolated from the meninges during meningitis
[14,15]. Approximately 23 serotypes are responsible for 80–
90% of IPD [16].
The serotype involved is also associated with severity of
disease, and the clinical impact of a pneumococcal vaccination
usually depends on the coverage of serotypes frequently
associated with invasive disease or antibiotic resistance.
Knowledge of local serotype predominance represents one
of the key points for a successful vaccination programme.
Serotypes 1, 3, 4, 6A, 6B, 7F, 8, 9V, 14, 18C, 19F and 23F are
the dominant serotypes associated with IPD worldwide [17].
However, this distribution may vary signiﬁcantly between
geographic locations.
The most frequent serotypes in Europe are 1, 3, 7F, 14 and
19a, but large differences can be found among countries, as
shown in Table 1 [18–25]. A recently published meta-analysis
showed that S. pneumoniae serotypes isolated from young
children with invasive pneumococcal diseases varied signiﬁ-
cantly from a geographical point of view. However, serotype
14 was the most common isolate throughout the world, and
serotypes 1, 5, 6A, 6B, 14, 19F and 23F were isolated in 50% of
individuals [26].
The four main principles of pneumococcal vaccine design
are: (i) cover as many serotypes as possible; (ii) cover the most
common serotypes; (iii) cover serotypes associated with
severe disease or antibiotic resistance; and (iv) ensure
longevity of immunity.
Pneumococcal polysaccharide vaccine
Streptococcus pneumoniae vaccines are based on the use of the
capsular polysaccharides, which induce type-speciﬁc antibodies
that activate and ﬁx complement and promote bacterial
opsonization and phagocytosis. The current pneumococcal
polysaccharide vaccine stimulates a humoral immune response
against the capsular polysaccharide on the surface of the
bacteria. The ﬁrst observation regarding the efﬁcacy of
pneumococcal vaccine was in 1911 in South Africa [27].
However, the ﬁrst advanced pneumococcal vaccine, which
included 14 different serotypes, was approved by the US Food
and Drug Administration (FDA) in 1977. It was changed to a
23-valent vaccine (PPV23) in 1983 with 25 lg of surface
polysaccharide of 23 different serotypes, including 1, 2, 3, 4, 5,
TABLE 1. Most prevalent serotypes in adult pneumococcal disease among nine European countries
1 2 3 4 5 6A 6B 7F 8 9V 11A 12F 14 15B 17F 18C 19A 19F 22F 23F
UK X X X X X X X X X X
Portugal X X X X X X
Greece X X X X X X
Spain X X X X X X X X X
France X X X X X
Germany X X X X X X X X X
Belgium X X X X X X X
Netherlands X X X X X X X X X X
Switzerland X X X X X X X X X X
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6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A,
20, 22F, 23F and 33F [28]. In the USA, almost 70% of the
elderly have been vaccinated with PPV23. This has led to a
reduction of IPD in adults. However, no reduction in IPD has
been documented in immunocompromised patients, and there
is little evidence for reductions in pneumococcal pneumonia
[29]. Furthermore, the effectiveness of PPV23 seems to
decrease with both age and time since vaccination, probably
because of a weak and short-lasting IgM immune response, the
absence of afﬁnity maturation and antibody class switching to
IgG. A lack of booster effect of re-vaccination limits the
effectiveness of vaccination to only a few years [30,31].
Recently, a Cochrane meta-analysis showed that PPV23 is
slightly effective in reducing IPD in healthy adults, but the
evidence for its effectiveness against all-cause mortality in
patients with pneumonia was inconclusive. Furthermore,
vaccine effectiveness in adults with chronic illness and with
immunosuppression appeared poor [32]. In 2008, WHO
indicated the need for a more effective conjugate vaccine or
other type of vaccines covering the pneumococcal serotypes
causing serious illness in both children and adults [33].
Pneumococcal conjugate vaccines
Conjugate vaccines seem to produce a stronger immune
response because of the combination of polysaccharide
protein antigen conjugate that is captured by B cells and other
antigen-presenting cells presenting antigens to T helper type 2
(Th2) cells. The activation of Th2 leads B cells to differentiate
into memory B cells and plasma cells. This results in a more
rapid production of antibodies in comparison to the switch
following primary antigen exposure [34]. Conjugate vaccines
have been used in children as well as in adults with defective
immune systems to promote a more robust immune response.
PCV7 is a conjugate pneumococcal vaccine that includes
fewer serotypes than PPV23: serotypes in PCV7 are 4, 6B, 9V,
14, 18C, 19F and 23F. Its introduction in US children has
reduced the incidence of IPD from >200 cases/100 000
persons to >50 cases/100 000 persons with a signiﬁcant herd
effect in the incidence of IPD in adults [35,36]. PCV7
vaccination has reduced the annual incidence of IPD and
pneumonia due to S. pneumoniae among children younger than
5 years by 97% for serotypes included in the vaccine, but
increased the incidence of infection due to non-vaccine
serotypes by 22% [37,38]. PCV7, but not PPV23, has been
shown to reduce IPD incidence in human immunodeﬁciency
virus (HIV)-infected adults [39]. Finally, PCV7 vaccination
seems to be more effective than PPV23 in adults in eliciting an
opsonophagocytic activity response at levels that are consid-
ered protective in children. However, real effects in reducing
IPD and pneumonia incidence in adults have not been
demonstrated [40]. PCV10 is a conjugate pneumococcal
vaccine that includes the serotypes covered by PCV7 plus
serotypes 1, 5 and 7F. The use of PCV10 in newborns resulted
in a reduction of the ﬁrst episodes of otitis media in 34% of
patients [41].
PCV13 is a conjugate pneumococcal vaccine that includes
the serotypes covered by PCV10 plus serotypes 3, 6A
(responsible for IPD) and 19A (responsible for antibiotic
resistance). The FDA licensed PCV13 for the prevention of
IPD and otitis media in infants and young children in February
2010. In December 2011, the FDA licensed this vaccine for
prevention of pneumonia and IPD in people aged ≥50 years
[42]. The use of PCV13 in children has decreased the incidence
of IPD by 36% and decreased IPD due to serotype 19A by 45%
(Kaplan SL, IDSA Annual Meeting 2011. Presentation LB1). A
recent survey among the adult population in Israel showed that
serotypes included in PCV7 and PCV13 matched 25.6% and
63.7% of pneumococcal serotype isolates and matched 30%
and 68% of serotypes in fatal cases, respectively; demonstrating
that the introduction of an adult vaccination programme with
PCV13 could be useful in reducing pneumococcal infections
[43]. The effectiveness of a PCV13 vaccination in adults could
be reduced by the increase in the incidence of other serotypes
not covered by this vaccine, as happened after the introduction
of PCV7 vaccination in children. The occurrence of this effect
became evident only after a considerable period of time.
PCV13 was introduced in the USA in 2010 and trends in
serotypes are not yet available. Finally, the use of a pneumo-
coccal vaccination programme based on PCV13 may be cost
effective according to several predictive models [44–46].
Suggestion for the use of pneumococcal vaccines
A large, randomized, placebo-controlled, clinical trial evaluat-
ing the efﬁcacy of PCV13 against non-bacteraemic community-
acquired pneumonia and IPD is in progress and results will be
available in 2014 [47]. However, there is some evidence for
the effectiveness of PPV13 in preventing pneumococcal-related
disease in adults. Preliminary data on the immune response to
PCV13 in adults are not yet available. However, the indications
for the use of PCV13 alone and in combination with PPV23
could be suggested. Vaccination with PPV23 is indicated in
adults >65 years in different countries, but the protective
effect against pneumococcal infection declines rapidly and is
inconsistent 3–5 years after the vaccination [48].
A randomized, controlled study enrolling 831 vaccine-naive,
immunocompetent adults aged 60–64 years and 403 adults
aged 50–59 years, showed that the response to 8 of 12
serotypes included in both vaccines was higher in subjects
vaccinated with PPV13 and in the younger cohort. The
opsonophagocytic activity declined from the ﬁrst month to
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1 year after vaccination, but remained higher than baseline
titres in PCV13. Future pneumococcal vaccination pro-
grammes could use PCV13 to reach a more robust immune
response and vaccinate people younger than 65 to prevent
vaccination failure due to immunosenescence [49].
Recommendations for adult pneumococcal vaccination
suggest a second dose of PPV23 after 5 years to overcome
the loss of immune protection, but data regarding the
effectiveness of this approach are lacking. It could be argued
that re-vaccination with PPV23 might not be useful to protect
people against pneumococcal infection 5 years after the ﬁrst
dose [50]. The advisory Committee on Immunization Practices
recently published a new recommendation for PCV13 [42].
They recommended PCV13 for adults >19 years old with
certain underlying disorders, including nephritic syndrome,
chronic renal failure, solid organ transplant, generalized
malignancy, HIV infection, iatrogenic immunodeﬁciency (such
as systemic corticosteroids), primary immunodeﬁciencies,
asplenia or sickle cell disease.
Re-vaccination with PCV13 could be an option for people
vaccinated with PPV23 to extend the protection against
pneumococcal infection. A preliminary, randomized, con-
trolled study enrolled 900 subjects >70 years who received
a second dose of vaccination with PCV13 or PPV23 after
receiving PCV13 or PPV23. In adults previously vaccinated
with PPV23, PCV13 elicited a statistically signiﬁcantly greater
opsonophagocytic activity response for the majority of
serotypes compared with a second vaccination with PPV23.
The responses to PCV13 given after PPV23 were signiﬁcantly
lower for all 13 serotypes compared with the initial PCV13
dose, indicating that PPV23 diminished the response to
subsequent PCV13. The responses after PCV13/PPV23 were
signiﬁcantly greater for 11 of 12 common serotypes compared
with PPV23/PCV13. This suggests that in adults who have
already received PPV23, there may be advantages to
subsequent administration of PCV13 rather than revaccination
with PPV23. A sub-analysis of different age groups in this study
showed that immune responses to PCV13 in elderly people
between 70–74 and 75–79 years of age were largely similar
and slightly lower in those aged 80 years and older [50]. The
administration of a second dose of PPV23 to subjects who had
received PPV23 3.5–4 years before has led to notably lower
immune responses than those observed following the initial
PPV23 [51]. However, a second dose of PCV13 produced a
response similar to the ﬁrst dose, and subjects who received
PCV13 as ﬁrst vaccine show a PPV23 response greater than
that due to a single dose of PPV23. These results suggest a
possible vaccination combination of PCV13 ﬁrst and PPV23
second with the aim being to obtain a prolonged and strong
immune protection against pneumococcal infection in people
older than 65 years. An indication for the use of PCV13 and
PPV23 in adults is shown in Fig. 1.
The presence of immunosuppression represents one of the
possible indications for pneumococcal vaccination. A study
performed in France among HIV-infected patients showed that
serotypes 19A, 14, 7F and 6A were the most frequent and
FIG. 1. PCV13 and PPV23: suggestions for pneumococcal vaccine use in immunocompetent patients. PCV13, pneumococcal 13-valent conjugate
vaccine; PPV23, pneumococcal polysaccharide 23-valent vaccine.
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S. pneumoniae isolates demonstrated higher levels of resis-
tance to b-lactams and cotrimoxazole. The PPV23 and PCV13
vaccines would have theoretically covered 78% and 70% of the
cases, respectively, potentially preventing difﬁcult-to-treat
S. pneumoniae infections [52]. In HIV-infected people a vacci-
nation regimen with PCV13, followed by PPV23, is clinically
and economically useful because of high pneumococcal disease
rates, increasing life expectancy and immune function mainte-
nance by antiretroviral therapy. However, in people with other
immunocompromising conditions associated with shorter life
expectancy and poorer immune responsiveness, adding PPV23
to PCV13 may be of less beneﬁt [53]. A suggestion for the use
of PCV13 and PPV23 in immunocompromised people is shown
in Fig. 2.
Conclusions
The new conjugate vaccine, PCV13, may provide an oppor-
tunity to reduce the burden of pneumococcal disease in both
children and adults. PCV13 seems to have a better balance
between serotype coverage and immunogenicity. Among
adults, PPV23 should not be offered as the ﬁrst vaccination
because of the lack of immunogenicity in the 3–5 years after
the vaccination, the lack of booster effect with a second dose,
and because of a reduction of immunogenicity effect from
PCV13. However, PPV23 seems to be useful as a second
vaccination 8 weeks after a PCV13 dose in order to increase
serotype coverage. Among immunocompromised patients,
PCV13 seems to be superior to PPV23 with regard to
immunogenic effects as well as cost effectiveness. This scenario
could be applicable not only in HIV-infected populations, but
also in other immunocompromised patients. So far, available
data are mainly based on the immunogenicity of the different
vaccines. More clinical data focused on the effectiveness of
vaccination for the reduction of pneumococcal disease will be
available in 2014 and may help with further evidence-based
recommendations.
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